Republican Congress To Shift Priorities, But Cancer May Get New Opportunities
In Brief: Ortho Biotec gives $1 Million To Fund Fatigue Initiative; Lippman, Pike Honored
NCI Won’t Recognize Wolmark Wile NSABP is Plaintiff In Suit
DCE Advisors Okay Contract Recompetitions For Epidemiology
Chemical Carcinogenesis
FDA Rile Changes Reporting Requirements for Adverse Events
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation